Carvajal Alejandra

SVP, Chief Legal OfficerMersana Therapeutics, Inc. (MRSN) · full profile →Form 4 · filed Jan 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
1 non-derivative · 12 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 6, 2026Tender(U)3K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 6, 2026Disposed to issuer(D)7K0
Jan 6, 2026Disposed to issuer(D)5K0
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)1K0
Jan 6, 2026Disposed to issuer(D)8K0
Jan 6, 2026Disposed to issuer(D)1000
Jan 6, 2026Disposed to issuer(D)7170
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)3K0
Jan 6, 2026Disposed to issuer(D)5K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-001380) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.